News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
Stable profits, low leverage to keep credit profiles comfortable
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
